Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia

Targeted therapy has been the forefront of cancer treatment. Cancer immunotherapy is the most recent focus. In addition, novel immunotherapeutics targeting B cell receptor signaling (e.g., ibrutinib), T cell receptor ( e.g., CART19), and NK cells (e.g., AFM13) are being developed. This review summar...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Hematol Oncol
Main Authors: Wu, Jingjing, Fu, Jiaping, Zhang, Mingzhi, Liu, Delong
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2015
Fag:
Review
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4558758/
https://ncbi.nlm.nih.gov/pubmed/26337639
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-015-0195-4
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker